[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531606":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":35,"collaborators":7,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":7,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":7,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":54,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Power Life Sciences Inc.","INDUSTRY",null,[9],{"name":10,"affiliation":5,"role":11},"Michael B Gill","STUDY_DIRECTOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","(415) 900-4227","bask@withpower.com",[18],{"facility":19,"status":7,"city":20,"state":21,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Power Life Sciences","San Francisco","California","94107","United States","US",{"type":26,"coordinates":27},"Point",[28,29],-122.41942,37.77493,{"lat":29,"lon":28},[32],{"name":10,"role":14,"phone":33,"phoneExt":7,"email":34},"415-900-4227","https:\u002F\u002Fwww.withpower.com\u002Fcontact-us@withpower.com",{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100531606","revealing-engagement-patterns-among-hepatic-encephalopathy-patients-100531606",false,"NCT06201988","Revealing Engagement Patterns Among Hepatic Encephalopathy Patients","Assessing Patient Engagement and Understanding in Hepatic Encephalopathy Clinical Research","Inclusion Criteria:\n\n* Signed Written Informed Consent\n* Aged ≥ 18 years old\n* No prior treatment for hepatic encephalopathy\n\nExclusion Criteria:\n\n* Participant is actively receiving study therapy in another\n* Inability to provide written informed consent\n* Women of childbearing potential without a negative pregnancy test; or women who are lactating.","ALL","18 Years",{"count":47,"type":48},500,"ESTIMATED","OBSERVATIONAL","This study aims to investigate the influences behind patient choices regarding involvement, discontinuation, or re-engagement in hepatic encephalopathy clinical trials. Uncovering these factors is essential to enhance the relevance and efficacy of future research endeavors.\n\nIn essence, this trial aims to deepen understanding of the factors influencing participation in hepatic encephalopathy clinical trials. Elevating participation rates could expedite the development of innovative treatments for this challenging condition.",[52],"Hepatic Encephalopathy",[52],"NOT_YET_RECRUITING","2024-02-09",{"date":57,"type":58},"2024-02-12","ACTUAL",{"date":60,"type":48},"2025-01",{"date":62,"type":48},"2027-01",{"name":5,"class":6},1]